INTRODUCTION

Meneldor offers her customers the unique opportunity to co-invest alongside specialists, in

exciting early stage Biotech and Pharma companies. A sector often considered as very risky

and highly complex. Meneldor thoroughly studies the science behind her potential portfolio

companies. If the science is sound, then all other key aspects; IP, medical need, addressable

markets, competition, risk, management, financial needs, valuation, etc., are assessed. Only if

a target company meets our selection criteria, Meneldor will invest and invite her co-investors

to participate.

INVESTMENT FOCUS

Meneldor focuses on early stage biotech and pharma companies that (re)develop (New) Bio or

Chemical Molecular Entities, that have outstanding technology with strong IP, address significant

unmet medical needs and attractive markets. We are especially scouting for companies that work

on relatively low risk and high growth opportunities. We mainly invest in projects which are in

preclinical, Phase I or Phase II and in indications with preferably clear well defined clinical

endpoints. Our geographic focus is Western Europe.

CURRENT HOLDINGS AND PIPELINE

Meneldor has a very exciting pipeline. Details will be shared only under NDA. Our current holdings are:

2016: Xenikos B.V. : Developing a drug therapy in acute Graft vs Host disease to reset the

immune system of the donated stem cells

2017: Atriva Therapeutics GmbH: Developing novel, broadly active anti-viral drugs with an

excellent benefit-risk profile

2018: Aptamer Group Ltd: Automated-DOE driven aptamer discovery platform for the

development of therapeutics and diagnostics

2019: LightOx Ltd: Developing fluorescent drugs that are capable of targeting selected cell types and killing them on illumination with light